GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Total Long-Term Liabilities

XSpray Pharma AB (STU:6XP) Total Long-Term Liabilities : €2.35 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. XSpray Pharma AB's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €2.35 Mil.

XSpray Pharma AB Total Long-Term Liabilities Historical Data

The historical data trend for XSpray Pharma AB's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Total Long-Term Liabilities Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.12 0.05 2.86 2.36

XSpray Pharma AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 2.65 2.52 2.36 2.35

XSpray Pharma AB Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

XSpray Pharma AB Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

XSpray Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Total Long-Term Liabilities
Comparable Companies
OSTO:SANION OSTO:EGTX OSTO:DMYD B OSTO:SYNACT OSTO:IBT B OSTO:HNSA XSAT:HAMLET B OSTO:FLUO OSTO:GENO OSTO:MAGLE VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
XSPRAY:Sweden 0GHZ:UK 6XP:Germany
Address
Scheeles vag 2, Solna, SWE, SE-171 65
Website
https://www.xspraypharma.com
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines